2026 Preview: Navigating Pharma’s Critical Year
The biopharma sector enters 2026 in qualified recovery. After years of tough financing and investor skepticism, green shoots are appearing, but not everyone benefits from the rebound.
This isn’t another boom. The industry emerging from the drought is smarter, leaner, and more selective. For the rally to build momentum, execution matters. And the stakes are high: $36bn in late-2025 M&A, looming patent cliffs, and seismic FDA shifts set the stage for a pivotal year.
The incretin wars intensify as Eli Lilly eclipses Novo Nordisk to lead metabolics, with tirzepatide set to drive the company to pharma’s first $75.5bn annual prescription sales. What will follow-on therapies in this arena bring?
Download your copy to discover:
- Leadership shifts: Which companies and drugs dominate the top line, and which face steep patent declines?
- Pipeline potential: The highest-value R&D projects launching in 2026, from obesity therapies to immunology breakthroughs
- Market dynamics: How $36bn in recent dealmaking reveals big pharma’s strategic priorities
- Regulatory outlook: What Trump administration changes mean for FDA productivity and approvals
- Investment landscape: Why the IPO window may open and where venture capital flows
Join over 4,000 biopharma professionals who depend on our annual Preview to stay ahead of market changes. This report is powered by Evaluate Pharma and Evaluate Omnium, providing essential competitive intelligence for strategic planning, opportunity evaluation, and portfolio optimization. Download the 2026 Preview for insights you need to make confident decisions in a constantly evolving landscape.
Explore these insights further with Evaluate’s industry experts in our 2026 Preview webinar on January 22nd. Register Here.
Access the report today – unlock the insights that shape 2026.
